Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysisArthur Kavanaugh, Philip J. Mease, Dafna D. Gladman et al.|Arthritis Research & Therapy|2019Cited by 80
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studiesDafna D. Gladman, Philip J. Mease, J. Wollenhaupt et al.|RMD Open|2018Cited by 38
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patientsAlvin F. Wells, Jacob Aelion, Christopher J Edwards et al.|Lara D. Veeken|2021Cited by 12
THU0294 5-year efficacy and safety of apremilast treatment in subjects with psoriatic arthritis: pooled analysis of the palace studiesArthur Kavanaugh, Philip J. Mease, Dafna D. Gladman et al.|Annals of the Rheumatic Diseases|2018Cited by 0
AB0905 Long-term (5-YEAR) efficacy and safety of apremilast monotherapy in dmard-naÏve subjects with active psoriatic arthritisA. Wells, Jacob Aelion, Christopher J Edwards et al.|Annals of the Rheumatic Diseases|2018Cited by 0